Just a few days before JPM, Crescendo Bioscience pulled in $28 million in Series D financing to boost commercialization efforts for its new rheumatoid arthritis molecular diagnostic test--on the market since 2010. And so William Hagstrom, Crescendo's president and CEO, was there, in part, to get the word out about his company's signature diagnostic and autoimmune diseases in general. As well, he focused on expanding partnerships with pharmaceutical companies that could use the diagnostic for other indications. Also on the table: Expanded strategic relationships with payers that cover treatments for RA and other autoimmune diseases, many of which are hard to bring under control. "These are diseases where the degree of disease control is limited," he said, making better diagnostics crucial.